<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578511</url>
  </required_header>
  <id_info>
    <org_study_id>PRO25835</org_study_id>
    <nct_id>NCT02578511</nct_id>
  </id_info>
  <brief_title>Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)</brief_title>
  <official_title>Standard Maintenance [POMP/D (Methotrexate, 6 - Mercaptopurine, Vincristine, Prednisone/Dexamethasone)] Plus Ixazomib Maintenance Therapy in Adults With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ehab L Atallah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase I study, escalating doses of IXAZOMIB will be combined with the POMP/D regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE

      The primary objective is to determine the maximum-tolerated dose of IXAZOMIB (MLN9708)
      (maximum of 4 mg, which is the recommended phase II dose for IXAZOMIB (MLN9708) in
      combination with standard maintenance therapy with POMP/D (methotrexate, 6- mercaptopurine,
      vincristine, prednisone/dexamethasone) and to assess the tolerability of POMP/D and IXAZOMIB
      (MLN9708) maintenance in adult patients with acute lymphoblastic leukemia, lymphoblastic
      lymphoma (LBL) or mixed phenotype acute leukemia (MPAL) in complete remission (CR).

      SECONDARY OBJECTIVE

      To determine the three-year progression-free survival (PFS) of patients treated with oral
      IXAZOMIB (MLN9708) and standard maintenance regimen. Progression-free survival will be
      measured from the start of induction to disease relapse.

      STUDY DESIGN

      The maximum-tolerated dose of single agent IXAZOMIB was 1.76 to 2.0mg/m2 when given on a
      twice a week schedule1 and &gt; 2.34 mg/m2 to 2.97 mg/m2 on a weekly schedule in previous
      studies.

      Three patients will be treated per dose level unless dose-limiting toxicity (DLT) is
      observed. The starting dose of IXAZOMIB will be 3 mg orally on days 1, 8 and 15. If no DLT is
      seen in the first three patients, the dose will be increased to 4 mg on days 1, 8 and 15 in a
      classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally
      which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2
      dose (RP2D). Zero of three DLTs would allow escalation to the next dose level. One of three
      DLTs will require expanding to six patients; one of six DLTs will allow escalation again. Two
      DLTs will require dose de-escalation. The maximum-tolerated dose (MTD) will be the highest
      dose administered at which no more than one DLT was observed.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No enrollment, another competing study and difficult to find the right person to enroll on this
    study.
  </why_stopped>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Actual">February 13, 2018</completion_date>
  <primary_completion_date type="Actual">February 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of ixazomib with POMP/D maintenance</measure>
    <time_frame>Eight (8) weeks</time_frame>
    <description>The patient cohort enrolled at each dose level will be monitored for dose-limiting toxicity for eight weeks prior to enrolling the next cohort of patients at a new dose level. Subsequent patient cohorts will be enrolled at doses according to the CRM design. A maximum sample size of 12 patients will be enrolled over four potential doses to determine the maximum tolerated dose of ixazomib with POMP/D maintenance. Adverse events will be summarized with descriptive statistics at each dose level of ixazomib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of patients treated with oral Ixazomib and standard maintenance regimen.</measure>
    <time_frame>Three (3) years</time_frame>
    <description>Progression-free survival will be measured from the time of diagnosis to disease relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Lymphoblastic Leukemia in Complete Remission</condition>
  <condition>Lymphoblastic Lymphoma in Complete Remission</condition>
  <condition>Mixed Phenotype Acute Leukemia in Complete Remission</condition>
  <arm_group>
    <arm_group_label>Ixazomib (MLN9708) in combination with standard POMP/D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.
Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib</intervention_name>
    <description>Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.</description>
    <arm_group_label>Ixazomib (MLN9708) in combination with standard POMP/D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients 18 years or older.

          -  Have B-precursor, T cell ALL, MPAL or LBL in CR following therapy and receiving
             maintenance therapy. Patients with persistent minimal residual disease and/or in
             complete remission with incomplete platelet recovery are not eligible.

          -  Prior therapy: Should have achieved CR following the induction and intensification
             phases of treatment, with no limit on the number of prior treatment regimens, and
             started treatment with POMP/D maintenance. Patients who achieved CRp or CR with
             persistence of minimal residual disease are not eligible.

          -  Patients are eligible after allogeneic stem cell transplantation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Patients must meet the following clinical laboratory criteria:

               -  Total bilirubin &lt; 1.5 X the upper limit of the normal range (ULN).

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase. (AST) &lt; 3 X ULN.

               -  Calculated creatinine clearance &gt; 30 mL/min.

               -  Absolute neutrophil count (ANC) &gt; 1,000/cmm and platelets &gt; 75,000/cmm.

          -  Patient has a life expectancy of at least six months.

          -  Patients must be at least two weeks from major surgery, radiation therapy,
             participation in other investigational trials and have recovered from clinically
             significant toxicities of these prior treatments.

          -  Patients should be on stable doses of 6-mercaptopurine, methotrexate, vincristine and
             prednisone/dexamethasone as part of the POMP/D regimen, for a minimum of eight weeks
             PRIOR to starting ixazomib treatment.

          -  Patients should have at least six months of therapy with the POMP/D regimen remaining
             prior to starting IXAZOMIB (MLN9708).

          -  Female patients who:

               -  Are postmenopausal for at least one year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice two effective. methods
                  of contraception, at the same time, from the time of signing the informed consent
                  form through 90 days after the last dose of study drug, AND

               -  Must also adhere to the guidelines of any treatment-specific pregnancy prevention
                  program, if applicable, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,
                  symptothermal, postovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Male patients, even if surgically sterilized (i.e., status postvasectomy), must agree
             to one of the following:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 90 days after the last dose of study drug, OR

               -  Must also adhere to the guidelines of any treatment-specific pregnancy prevention
                  program, if applicable, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation,
                  symptothermal, postovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

        Exclusion criteria:

          -  Systemic treatment, within 14 days before study enrollment, with strong CYP3A inducers
             (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of
             ginkgo biloba or St. John's wort.

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, or psychiatric illness/social
             situations that would limit compliance with study requirements. Patients should not
             have evidence of active infection.

          -  Inability to swallow oral medication, inability or unwillingness to comply with the
             drug administration requirements, or GI procedure that could interfere with the oral
             absorption or tolerance of treatment.

          -  Active chronic graft vs. host disease requiring therapy.

          -  Patient has â‰¥ grade 2 peripheral neuropathy.

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the trial start and throughout the duration of this
             trial.

          -  Failure to have fully recovered (i.e., &lt; grade 1 toxicity) from the reversible effects
             of prior chemotherapy.

          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past six months.

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with treatment completion according to this protocol.

          -  Known allergy to any of the study medications, their analogues or excipients in the
             various formulations of any agent.

          -  Diagnosed or treated for another malignancy within two years before study enrollment
             or previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

          -  Female patients who are breastfeeding or have a positive serum pregnancy test during
             the screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab Atallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Ehab L Atallah</investigator_full_name>
    <investigator_title>Associate Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia in Complete Remission</keyword>
  <keyword>Lymphoblastic Lymphoma in Complete Remission</keyword>
  <keyword>Mixed Phenotype Acute Leukemia in Complete Remission</keyword>
  <keyword>IXAZOMIB</keyword>
  <keyword>POMP/D</keyword>
  <keyword>Phase I</keyword>
  <keyword>Early Phase</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Lymphoblastic Lymphoma</keyword>
  <keyword>Mixed Phenotype Acute Leukemia</keyword>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

